BC Innovations | Jun 27, 2013
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Functionalized, methacrylated hyaluronic acid hydrogels for cartilage repair Methacrylated hyaluronic acid hydrogels functionalized with N-cadherin mimetic peptides could be useful for...
BC Week In Review | Apr 11, 2011
Clinical News

Tarceva erlotinib: Additional Phase II data

Researchers at the M.D. Anderson Cancer Center reported additional data from a subgroup of 101 stage IV NSCLC patients who had gene expression profiles obtained from pretreatment core needle biopsies in the adaptive, open-label, U.S....
BC Innovations | Dec 2, 2010
Cover Story

N-Cadherin block against prostate cancer

University of California, Los Angeles researchers have shown that mAbs targeting the cell surface protein N-cadherin can inhibit prostate cancer growth, metastasis and progression to castration-resistant disease. 1 If Emtx Therapeutics Inc. exercises its option...
BC Innovations | Dec 2, 2010
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer N-Cadherin Studies in mice suggest that blocking N-cadherin could help treat and prevent castration-resistant prostate cancer (CRPC). In multiple...
BC Innovations | May 7, 2009
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer N-cadherin; snail1; twist homolog (TWIST); vimentin (VIM); Y box-binding protein I (YB1) A mouse and cell-culture study suggests that...
BC Week In Review | Nov 17, 2008
Company News

Adherex cancer news

Adherex will rationalize its clinical programs to conserve cash. The company will focus on its Phase III trials of sodium thiosulfate (STS) to treat liver cancer and to prevent hearing loss in children receiving cisplatin-based...
BC Week In Review | Jun 9, 2008
Clinical News

ADH-1: Interim Phase I/IIb data

Data from 20 evaluable patients in an ongoing, U.S. Phase I/IIb trial (AHX-01-007) showed that ADH-1 plus melphalan produced 10 complete responses at 3 months of follow-up. The trial is expected to enroll 56 patients....
BC Week In Review | May 26, 2008
Clinical News

ADH-1: Phase I/IIb data

Data from 16 evaluable patients in an ongoing, U.S. Phase I/llb trial (AHX-01-007) showed 8 complete responses at 3 months, following treatment with ADH-1 plus isolated limb infusion of melphalan. Additional data will be presented...
BC Innovations | Apr 10, 2008
Cover Story

Metastasis, Interrupted

Two studies have clarified the roles of two different proteins in metastasis, suggesting potential new therapeutic strategies to treat cancer. One study proposes agonizing the membrane protein CD151 to prevent cancer cells from mobilizing at...
BC Innovations | Apr 3, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker /pathway Summary Licensing status Publication and contact information Cancer Metastasis CD151; CD44; epithelial cell adhesion molecule (EpCAM) In vivo studies suggest that antagonizing CD151 could help prevent metastasis in...
Items per page:
1 - 10 of 46